Why does the diagnosis matter if the symptoms look similar?

Treatment response and progression are very different across these conditions. People with PSP and MSA often respond poorly to levodopa, so a Parkinson's medication that helps one person may not help another. Clinical trial eligibility is also condition-specific, so the right diagnosis opens or closes the right doors.

How is Lewy body dementia different from Parkinson's dementia?

The biology is closely related, but the timing differs. In Parkinson's disease dementia, motor symptoms start first and cognitive changes appear years later. In dementia with Lewy bodies, cognitive symptoms appear early, sometimes before any motor signs. The same protein, alpha-synuclein, is involved in both.

Are there clinical trials specifically for PSP, MSA, or Lewy body dementia?

Yes, and they are growing. Several active trials target alpha-synuclein in MSA and DLB, and tau-directed therapies are being studied for PSP. These trials have very specific eligibility criteria, so a confirmed diagnosis from a movement disorders specialist matters.

Can a diagnosis of Parkinson's change to one of the atypical conditions later?

Yes. The first one to two years after a Parkinson's diagnosis often involves watching how symptoms evolve. If symptoms progress unusually quickly, do not respond to levodopa, or include early falls, swallowing problems, or significant cognitive changes, doctors may revisit the diagnosis. A second opinion from a movement disorders specialist is reasonable when something does not feel right.

Where can I find a doctor who specializes in atypical parkinsonisms?

Movement disorders clinics at academic medical centers usually have specialists who see PSP, MSA, and DLB regularly. The CurePSP and MSA Coalition websites maintain directories of providers experienced with these conditions.

Parkinson's vs Lewy Body Dementia vs PSP vs MSA: Telling Parkinsonisms Apart

Several conditions can look like Parkinson's at the very beginning, especially in the first year or two. Doctors call them parkinsonisms, an umbrella term for any condition that produces some of the same motor signs as Parkinson's disease. The most common atypical parkinsonisms are dementia with Lewy bodies, progressive supranuclear palsy, and multiple system atrophy.

Telling them apart matters for treatment, for what to expect, and for which clinical trials someone might be eligible for.

Why This Confusion Exists

All four conditions involve overlapping regions of the brain and produce overlapping early symptoms, slowness of movement, stiffness, balance trouble, sometimes tremor. Early on, even experienced neurologists can find them hard to tell apart. Diagnosis often becomes clearer over time as the pattern of symptoms develops.

Parkinson's Disease (PD)

The most common parkinsonism. Caused primarily by the gradual loss of dopamine-producing neurons in the substantia nigra, with alpha-synuclein protein clumping believed to drive much of the damage. Symptoms typically begin on one side of the body and may include tremor at rest, stiffness, slowness, and changes in handwriting or facial expression.

People with Parkinson's usually respond well to levodopa, often dramatically so, and live for many years with the disease. Cognitive changes, when they happen, generally appear later in the course of the illness.

Lewy Body Dementia (DLB and PDD)

Lewy body dementia is the umbrella term for two closely related conditions, dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Both involve the same alpha-synuclein protein clumping seen in Parkinson's, but the timing of symptoms is different.

In DLB, cognitive changes appear first, often before any obvious motor signs, and may include detailed visual hallucinations, fluctuating attention, and acting out dreams during sleep (REM sleep behavior disorder). Motor symptoms develop later. In PDD, motor symptoms come first and dementia develops at least a year after diagnosis.

Levodopa response in DLB is variable and can sometimes worsen hallucinations. Standard antipsychotic medications can be dangerous for people with Lewy body dementia and should be avoided.

Progressive Supranuclear Palsy (PSP)

PSP is a rarer condition driven by the buildup of a different protein, tau, in specific brain regions. Hallmarks include early balance problems with backward falls within the first year of symptoms, difficulty moving the eyes vertically, slowed speech and swallowing, and a staring expression. Tremor is uncommon.

People with PSP usually do not respond well to levodopa. Progression is faster than typical Parkinson's, and the condition is often misdiagnosed as Parkinson's for the first year or two until the distinct features become obvious.

Multiple System Atrophy (MSA)

MSA is another alpha-synuclein condition, but the protein clumps form in glial cells (the brain's support cells) rather than in neurons. There are two main forms, MSA-P which looks more like Parkinson's, and MSA-C which features more cerebellar symptoms like balance and coordination problems.

Telltale features include severe drops in blood pressure when standing (orthostatic hypotension), bladder problems early in the disease, and rapid progression compared with typical Parkinson's. Levodopa may help briefly but the response usually fades within a year or two.

A Side by Side Look

Underlying biology. PD and DLB and MSA all involve alpha-synuclein. PSP involves tau.
Levodopa response. Usually strong and lasting in PD. Variable in DLB. Brief or absent in PSP. Brief in MSA.
Earliest symptoms. Motor on one side in PD. Cognitive changes and hallucinations in DLB. Backward falls and eye-movement problems in PSP. Blood pressure drops and bladder problems in MSA.
Progression speed. Slowest in PD. Faster in PSP and MSA. Variable in DLB depending on subtype.
Tremor. Common in PD. Less common in DLB. Uncommon in PSP. Uncommon in MSA.

Why the Distinction Matters for Trials

Clinical trial eligibility is condition-specific. A trial recruiting people with idiopathic Parkinson's will exclude people with PSP, MSA, or DLB because the underlying biology is different and the response to a treatment is likely to be different too. There are also condition-specific trials. Several active trials target alpha-synuclein in MSA and DLB, and tau-directed therapies are being studied for PSP. The right diagnosis opens or closes the right doors.

Browse Parkinson's trials on Parkinson's Pathways, or search ClinicalTrials.gov directly for trials specific to PSP, MSA, or Lewy body dementia.

If You Are Not Sure Which One You Have

The single most useful step is a visit with a movement disorders specialist, ideally at an academic medical center. These are neurologists with deep experience telling these conditions apart, and they can order the imaging and detailed neurological assessments that help distinguish them. Diagnosis often clarifies over time as the pattern of symptoms develops, so a follow-up at six to twelve months is reasonable when the picture is unclear.

A Note on the Word Parkinsonism

Parkinsonism is a description, not a diagnosis. It just means a person shows some of the motor features of Parkinson's, slowness, stiffness, tremor, balance problems. Behind that description is the harder question of which underlying condition is causing it. PD, DLB, PSP, and MSA are the four most common answers, and the difference between them shapes what comes next.

Frequently Asked Questions

Why does the diagnosis matter if the symptoms look similar?: Treatment response and progression are very different across these conditions. People with PSP and MSA often respond poorly to levodopa, so a Parkinson's medication that helps one person may not help another. Clinical trial eligibility is also condition-specific, so the right diagnosis opens or closes the right doors.
How is Lewy body dementia different from Parkinson's dementia?: The biology is closely related, but the timing differs. In Parkinson's disease dementia, motor symptoms start first and cognitive changes appear years later. In dementia with Lewy bodies, cognitive symptoms appear early, sometimes before any motor signs. The same protein, alpha-synuclein, is involved in both.
Are there clinical trials specifically for PSP, MSA, or Lewy body dementia?: Yes, and they are growing. Several active trials target alpha-synuclein in MSA and DLB, and tau-directed therapies are being studied for PSP. These trials have very specific eligibility criteria, so a confirmed diagnosis from a movement disorders specialist matters.
Can a diagnosis of Parkinson's change to one of the atypical conditions later?: Yes. The first one to two years after a Parkinson's diagnosis often involves watching how symptoms evolve. If symptoms progress unusually quickly, do not respond to levodopa, or include early falls, swallowing problems, or significant cognitive changes, doctors may revisit the diagnosis. A second opinion from a movement disorders specialist is reasonable when something does not feel right.
Where can I find a doctor who specializes in atypical parkinsonisms?: Movement disorders clinics at academic medical centers usually have specialists who see PSP, MSA, and DLB regularly. The CurePSP and MSA Coalition websites maintain directories of providers experienced with these conditions.